These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8504625)

  • 1. Pharmacokinetics of temocapril and enalapril in patients with various degrees of renal insufficiency.
    Oguchi H; Miyasaka M; Koiwai T; Tokunaga S; Hora K; Sato K; Yoshie T; Shioya H; Furuta S
    Clin Pharmacokinet; 1993 May; 24(5):421-7. PubMed ID: 8504625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose pharmacokinetics of temocapril and temocapril diacid in subjects with varying degrees of renal impairment.
    Sierakowski B; Püchler K; Witte PU; Renneisen K; Roots I
    Eur J Clin Pharmacol; 1997; 53(3-4):215-20. PubMed ID: 9476034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of temocapril hydrochloride, a novel angiotensin converting enzyme inhibitor, in renal insufficiency.
    Nakashima M; Yamamoto J; Shibata M; Uematsu T; Shinjo H; Akahori T; Shioya H; Sugiyama K; Kawahara Y
    Eur J Clin Pharmacol; 1992; 43(6):657-9. PubMed ID: 1493850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of temocapril, an ACE inhibitor with preferential biliary excretion, in patients with impaired liver function.
    Furuta S; Kiyosawa K; Higuchi M; Kasahara H; Saito H; Shioya H; Oguchi H
    Eur J Clin Pharmacol; 1993; 44(4):383-5. PubMed ID: 8513851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of temocapril and temocaprilat after 14 once daily oral doses of temocapril in hypertensive patients with varying degrees of renal impairment.
    Püchler K; Eckl KM; Fritsche L; Renneisen K; Neumayer HH; Sierakowski B; Lavrijssen AT; Thomsen T; Roots I
    Br J Clin Pharmacol; 1997 Dec; 44(6):531-6. PubMed ID: 9431827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS-622) in humans.
    Suzuki H; Kawaratani T; Shioya H; Uji Y; Saruta T
    Biopharm Drug Dispos; 1993 Jan; 14(1):41-50. PubMed ID: 8427943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic effects of temocapril in hypertensive patients with diabetes mellitus type 2.
    Lerch M; Weidmann P; Ho MP; Gerber P; Eckenberger P; Kaemmereit A; Teuscher AU
    J Cardiovasc Pharmacol; 1999 Apr; 33(4):527-33. PubMed ID: 10218721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency.
    Sica DA; Cutler RE; Parmer RJ; Ford NF
    Clin Pharmacokinet; 1991 May; 20(5):420-7. PubMed ID: 1652404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.
    Hoyer J; Schulte KL; Lenz T
    Clin Pharmacokinet; 1993 Mar; 24(3):230-54. PubMed ID: 8462229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placental passage of angiotensin-converting enzyme inhibitors.
    Reisenberger K; Egarter C; Sternberger B; Eckenberger P; Eberle E; Weissenbacher ER
    Am J Obstet Gynecol; 1996 May; 174(5):1450-5. PubMed ID: 9065110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different accumulation of temocapril and enalapril during repeated dosing in elderly patients.
    Arakawa M; Ohmori M; Harada K; Araki N; Saitoh T; Fujimura A
    Br J Clin Pharmacol; 2005 Apr; 59(4):489-90. PubMed ID: 15801948
    [No Abstract]   [Full Text] [Related]  

  • 12. Disposition and safety of omapatrilat in subjects with renal impairment.
    Sica DA; Liao W; Gehr TW; Khan S; Jemal M; Delaney CL; Ferreira IM; Malhotra BK
    Clin Pharmacol Ther; 2000 Sep; 68(3):261-9. PubMed ID: 11014407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological and clinical studies with temocapril, an angiotensin converting enzyme inhibitor that is excreted in the bile.
    Yasunari K; Maeda K; Nakamura M; Watanabe T; Yoshikawa J; Asada A
    Cardiovasc Drug Rev; 2004; 22(3):189-98. PubMed ID: 15492767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of spirapril in renal impairment.
    Meredith PA; Grass P; Guitard C; Elliott HL
    Blood Press Suppl; 1994; 2():14-9. PubMed ID: 8061840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites.
    Lefebvre HP; Laroute V; Concordet D; Toutain PL
    J Vet Intern Med; 1999; 13(1):21-7. PubMed ID: 10052059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of the newer ACE inhibitors. A review.
    Kelly JG; O'Malley K
    Clin Pharmacokinet; 1990 Sep; 19(3):177-96. PubMed ID: 2203579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profiles of CS-622, a novel angiotensin converting enzyme inhibitor.
    Oizumi K; Koike H; Sada T; Miyamoto M; Nishino H; Matsushita Y; Iijima Y; Yanagisawa H
    Jpn J Pharmacol; 1988 Nov; 48(3):349-56. PubMed ID: 2851680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of long-term therapeutic effect of an ACE inhibitor, temocapril, with that of a diuretic on microalbuminuria in non-diabetic essential hypertension.
    Shionoiri H; Kosaka T; Kita E; Takizawa T; Takasaki I
    Hypertens Res; 2000 Nov; 23(6):593-600. PubMed ID: 11131271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients.
    Püchler K; Sierakowski B; Roots I
    Br J Clin Pharmacol; 1998 Oct; 46(4):363-7. PubMed ID: 9803985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
    Maeda K; Ieiri I; Yasuda K; Fujino A; Fujiwara H; Otsubo K; Hirano M; Watanabe T; Kitamura Y; Kusuhara H; Sugiyama Y
    Clin Pharmacol Ther; 2006 May; 79(5):427-39. PubMed ID: 16678545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.